Pfizer posts Phase 3 data for Lyme vaccine candidate LB6V at IDWeek 2026

By Public Technologies
  • Pfizer flagged Phase 3 results for its LB6V Lyme disease vaccine candidate, with IDWeek 2026 presentations scheduled Oct. 22.
  • The readout supported the shot’s ability to protect against Lyme disease, strengthening its case as a potential new commercial vaccine entrant.
  • Regulatory momentum advanced in Europe, with the EMA starting its review of the marketing application in August 2026.
  • Separate IDWeek 2026 presentations will cover Phase 2 data for a 25-valent pediatric pneumococcal candidate, with results previously announced in May 2026.
  • Pfizer also highlighted Phase 3 findings for an LP.8.1-adapted Comirnaty formulation in at-risk children, supporting its updated COVID-19 franchise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014474581) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.